We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+17.95%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$10.2B
AUM Growth
+$1.96B
(+24%)
Cap. Flow
+$643M
Cap. Flow
% of AUM
6.28%
Top 10 Holdings %
Top 10 Hldgs %
43.19%
Holding
1,081
New
132
Increased
418
Reduced
456
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$264M |
| 2 |
VanEck Gold Miners ETF
GDX
|
+$122M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$92.9M |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
+$52M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$26.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
+$92.8M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$32.9M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
+$15.4M |
| 4 |
Lockheed Martin
LMT
|
+$14M |
| 5 |
Apple
AAPL
|
+$9.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.61% |
| 2 | Financials | 16.65% |
| 3 | Industrials | 3.29% |
| 4 | Energy | 3.1% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Denali Therapeutics
DNLI
$3.67B
| $976K | 0.01% |
11,650
-27,468
| -70% | -$1.66M |
|
|
FOLD
502
DELISTED
Amicus Therapeutics
FOLD
| $974K | 0.01% |
42,180
-111,751
| -73% | -$2.29M |
|
503
Acadia Pharmaceuticals
ACAD
$4.39B
| $972K | 0.01% |
18,186
-35,995
| -66% | -$1.79M |
|
504
Halozyme
HALO
$9.76B
| $970K | 0.01% |
22,710
-50,641
| -69% | -$1.82M |
|
505
Alaska Air
ALK
$5.6B
| $969K | 0.01% |
18,633
+5,008
| +37% | +$225K |
|
506
Southwest Airlines
LUV
$23B
| $968K | 0.01% |
20,774
+6,282
| +43% | +$272K |
|
507
Arrowhead Research
ARWR
$12.1B
| $966K | 0.01% |
12,587
-47,158
| -79% | -$3.02M |
|
508
Natera
NTRA
$38.7B
| $961K | 0.01% |
9,655
-23,632
| -71% | -$1.97M |
|
|
XLRN
509
DELISTED
Acceleron Pharma
XLRN
| $960K | 0.01% |
7,501
-14,448
| -66% | -$1.69M |
|
|
TPTX
510
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $958K | 0.01% |
7,859
-17,350
| -69% | -$1.9M |
|
511
Bankunited
BKU
$3.4B
| $955K | 0.01% |
27,455
-13,351
| -33% | -$381K |
|
512
GE Aerospace
GE
$383B
| $954K | 0.01% |
17,718
+6,719
| +61% | +$301K |
|
513
Intellia Therapeutics
NTLA
$1.5B
| $952K | 0.01% |
17,504
-64,161
| -79% | -$2.33M |
|
|
CCXI
514
DELISTED
ChemoCentryx, Inc.
CCXI
| $951K | 0.01% |
15,355
-25,920
| -63% | -$1.48M |
|
515
Jazz Pharmaceuticals
JAZZ
$15.8B
| $950K | 0.01% |
5,758
+410
| +8% | +$61.1K |
|
516
Sarepta Therapeutics
SRPT
$1.68B
| $950K | 0.01% |
5,574
-9,607
| -63% | -$1.42M |
|
517
Exelixis
EXEL
$13.8B
| $942K | 0.01% |
46,916
-44,393
| -49% | -$929K |
|
518
Delta Air Lines
DAL
$60.2B
| $940K | 0.01% |
23,369
+9,285
| +66% | +$338K |
|
519
Seres Therapeutics
MCRB
$48.7M
| $938K | 0.01% |
+1,915
| New | +$1.12M |
|
520
Alnylam Pharmaceuticals
ALNY
$29.5B
| $934K | 0.01% |
7,189
-9,017
| -56% | -$1.2M |
|
|
SGMO
521
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $934K | 0.01% |
59,861
-128,740
| -68% | -$1.51M |
|
|
DCPH
522
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $934K | 0.01% |
16,361
-26,269
| -62% | -$1.56M |
|
523
Procter & Gamble
PG
$338B
| $933K | 0.01% |
6,702
-2,205
| -25% | -$308K |
|
|
ADVM
524
DELISTED
Adverum Biotechnologies
ADVM
| $930K | 0.01% |
8,583
-7,452
| -46% | -$922K |
|
525
Twist Bioscience
TWST
$6.29B
| $930K | 0.01% |
6,581
-25,161
| -79% | -$2.79M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Rafferty Asset Management held 1,081 positions worth $10.2B, up 24% from $8.27B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Rafferty Asset Management deployed $643M of net new capital in Q4 2020, opening 132 new positions and adding to 418 existing holdings. Its largest new stake was Keurig Dr Pepper: 119,771 shares worth $3.83M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was State Street SPDR S&P Oil & Gas Exploration & Production ETF, an estimated $92.8M trimmed.
- Rafferty Asset Management's largest Q4 2020 buy was Keurig Dr Pepper: 119,771 shares worth $3.83M.
- Rafferty Asset Management added most to iShares Russell 2000 ETF in Q4 2020, an estimated $264M increase.
- Rafferty Asset Management's biggest Q4 2020 reduction was State Street SPDR S&P Oil & Gas Exploration & Production ETF, cutting an estimated $92.8M.
- Rafferty Asset Management fully exited iShares MSCI EAFE ETF in Q4 2020, selling an estimated $4.41M.
- Rafferty Asset Management's ten largest holdings make up 43% of its $10.2B portfolio in Q4 2020.
- Rafferty Asset Management opened 132 new positions and closed 74 in Q4 2020.
- Rafferty Asset Management's portfolio value rose 24% quarter-over-quarter to $10.2B.
Based on Rafferty Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.